FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ACTOPLUS MET (pioglitazone and metformin hydrochloride) filed by Takeda to update the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ACTOPLUS MET (pioglitazone and metformin hydrochloride)

Snippet

SUPPL AP for ACTOPLUS MET (PIOGLITAZONE AND METFORMIN HYDROCHLORIDE)